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S  Seminal  studies  K  Key studies  R  Reviews  G  Guidance  MORE  Search for more studies
K  Advancing recovery in US states  (2012). Implementing medication-ass isted therapies  required regulatory, financing and contractual  levers  to overcome staff
res istance.
K  Case management l inks  detoxi fication to treatment (2006). Si ting case managers  at detoxi fication services  transformed them in to gateways  to longer term
treatment, part of a  broader ‘recovery revolution’ in Phi ladelphia. Link is  to Findings  analys is ; original  article a lso freely avai lable.
K  Dual  diagnosis  provis ion in England ([UK] Care Services  Improvement Partnership, 2008). Fi rst national  assessment for England of progress  towards
implementing government guidel ines. Regional  reports  a lso avai lable.
K  No impact of dual  diagnosis  tra ining for UK mental  health workers  (2007). Tests  guidance that mental  health teams should lead care of dual  diagnosis  patients .
Found no evidence that tra ining staff to del iver integrated dual  diagnosis  care improved substance use outcomes for psychotic patients . Article freely avai lable.
K  Truly integrated dual  diagnosis  care does  work (2006). Rare test of truly integrated substance use and mental  health care for severe mental  i l lness  found i t
reduced the number of subsequent psychiatric and legal  crises .
R  Link methadone maintenance with recovery resources  (2010). Review and guidance on reorienting methadone maintenance to recovery objectives  from leading
US author; includes  enhancing treatment’s  benefi ts  through l inking to/developing community resources, plus  local  campaigns  and advocacy to reduce stigma and
generate support for methadone programmes.
R  Incons istent benefi ts  from integrated mental  health/substance use treatment (2013). Meta-analytic synthes is  of US studies  finds  integrated treatment modestly
helps  resolve psychiatric symptoms, but a l ternative treatments  focused on this  i ssue are more effective in reducing drug use, especial ly when del ivered in
outpatient settings . Only one of the studies  assessed whether treatment truly was  integrated.
R  Paying health profess ionals  to do better (Cochrane review, 2011). Some evidence that financial  incentives  for workers  or provider organisations  can affect
processes  of care, but no evidence of improved patient outcomes. Reviewed studies  not speci fic to substance use. Simi lar message from review (Cochrane review,
2011) of paying primary care doctors  or teams. None of the smoking studies  found payment led to s igni ficantly more patients  giving up, including this  German
study (2007) which paid GPs  for each patient no longer smoking 12 months  later.
G  Commiss ioning for recovery ([UK] National  Treatment Agency for Substance Misuse, 2010).
G  UK consensus  on medications  as  a  route to recovery ([UK] National  Treatment Agency for Substance Misuse, 2012). UK cl inical  consensus, including how
medications  fi t in to an overal l  treatment system oriented to long-term recovery.
G  Opioid substi tute prescribing and recovery-oriented treatment in Scotland (Scottish Drug Strategy Del ivery Commiss ion, 2013). Expert group on what a  recovery-
oriented treatment system should look l ike, progress  towards  i t in Scotland, and the role of methadone maintenance and al l ied programmes within such a system.
G  Integrated care for substance users  in Scotland (Report Produced for the Scottish Advisory Committee on Drug Misuse, 2008). Treatment system guidance
including care pathways  and dual  diagnosis .
G  Guidance for commiss ioners  from Bri tish medical  col leges  ([UK] Joint Commiss ioning Panel  for Mental  Health, 2013). Col laboration of leading organisations
and individuals  involved in commiss ioning for mental  health offers  practical  advice on commiss ioning effective and efficient drug and alcohol  treatment services .
Group was led by England’s  Royal  Col lege of General  Practi tioners  and the Royal  Col lege of Psychiatrists .
G  Pharmacological  treatment of opioid dependence (World Health Organization, 2009). Recommends that opioid maintenance (eg, us ing methadone) should form
the backbone of treatment systems for addiction to opiate-type drugs  l ike heroin.
G  Pharmaceutical  services  for drug users  ([UK] National  Treatment Agency for Substance Misuse, 2006). Commiss ioning pharmacy services  to contribute to
treating and reducing harm from problem drug use.
G  Systems for treating mental ly i l l  problem substance users  ([UK] Department of Health, 2002). Key message is  that mainstream mental  health services  should
lead on treating ‘dual  diagnosis ’ patients , coordinating care with specia l is t substance misuse services . Later rei terated in guidance ([UK] National  Insti tute for
Health and Cl inical  Excel lence, 2011) issued by NICE speci fic to substance us ing psychotics .
MORE  This  search retrieves  a l l  relevant analyses .
For subtopics  go to the subject search page and hot topics  on commiss ioning and dual  diagnosis .
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What is this cell about? The roles of medical services and interventions within treatment systems implemented across an administrative
area; in particular, their role in creating an effective and cost-effective mix of services which offers patients/clients attractive access
points and appropriate options for moving between services or using them in parallel. Involves commissioning, contracting and
purchasing decisions to meet local needs in the context of resource constraints and national policy. Activities include: needs assessment;
restructuring or re-tendering services; contractual requirements on services to demonstrate evidence-based practice, meet standards,
and implement performance monitoring; and financial or other rewards/sanctions linked to activity, quality or outcomes. At this distance
from the preoccupation with intervention effectiveness, research is scarce, and rarely of the ‘gold standard’ randomised controlled trial
format. Work focusing on medical services is rarer still, but we can fall back on the studies and reviews which deal with similar issues
across drug treatment, to be found in cell E2
Where should I start? Perhaps with this recent guidance from a collaboration led by England’s general practitioner and psychiatry
colleges. It offers commissioning advice geared to the recovery and outcome-funding era. Among other reports it takes in to account the
current national drug strategy for England, NICE guidance and standards, the latest UK expert consensus on medications as recovery aids
in drug addiction, and guidance for England on commissioning for recovery. Commissioning should, said the expert group, be “outcome
based” and “recognise recovery as central”. They also boldly specified what in their opinion a good drug and alcohol service would look
like – of which more below.
Highlighted study Here’s a simple idea from Philadelphia, noted for the recovery-oriented transformation of its treatment system. The
study was concerned with Philadelphia’s detoxification centres, whose patients typically experienced multiple drug problems, usually
cocaine, alcohol, and cannabis, though around a third were problem heroin users. The issue addressed was that too often detoxification
was an isolated episode of care followed by relapse and then another detoxification. The attempted solution was to site clinical case
managers at the detoxification centres and task them with contacting patients who had been cycling repeatedly through withdrawal,
seemingly getting nowhere in terms of sustainably overcoming dependence. Case managers sought to motivate these patients to
complete detoxification and (for at least a year) offered to guide and support them through the follow-on services needed to sustain their
recovery. The initiative transformed these revolving-door patients in to patients with typical treatment admission patterns. Benefits were
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apparent across the entire caseload of the detoxification centres in increased capacity (the number of patients treated rose by well over
a half), a halving in the proportions of admissions accounted for by repeated detoxifications, and more successful referrals to longer term
care following detoxification. This simple tactic offers one way to make a reality of the continuing care advocated by experts convened by
UK medical colleges and now seen as an essential element of recovery-oriented treatment which matches the chronic nature of the kinds
of dependence/patients seen by treatment services.
Issues to think about
 What would a good quality drug service look like? The vision presented in this report of what commissioners should be looking for in
a drug (and alcohol) treatment service is not to be taken lightly, coming as it does from a heavyweight collaboration led by England’s
general practitioner and psychiatry colleges. Take a look at the specifications on page 14 of the report. Note that the list is subheaded,
“Key components of a good quality service”. The experts presumably saw these attributes as the minimum to justify a ‘good quality’ tag.
On the following page of the report you will find their recommended “Model of service delivery and core principles.” Take a look at both.
Is this also your vision of what a treatment service should look like and how it should work?
You could discuss the criteria with colleagues and benchmark services in your area against them, checking whether the criteria seem
relevant and appropriate. Here’s some suggested starter questions: Are these the attributes to be expected of each individual service, or
(perhaps more realistically) of the local service network? Services which meet these criteria can be expected to deliver good outcomes for
patients, but why not simply recognise what is or is not a good quality service by how well its patients do, regardless of how it is
organised and staffed? Can we specify what constitutes a good quality service in isolation from the local service and case-mix context;
could good quality in one area be poor in another? Is this a universally applicable vision, or one particular to a certain kind of service –
the “specialist integrated” teams staffed by “professional health and social care staff” which the report (page 15) sees as the best model
for addiction treatment? Do you also see a specialist, professional, and multidisciplinary team as the ideal? What of the GP-led services
which in the national English NTORS study matched specialist clinics for outcomes? Of course, medical competence is essential, but is it
a driver of recovery? Look back at the bite on practitioners in medical treatment. There we cite this advice from a review of why patients
do better with one clinician than another: “Select and evaluate clinicians based on their ‘track record’ ... assumptions that levels of
training, experience, or other simple therapist variables could account for such differences [in effectiveness] does not hold”. In the same
cell the Highlighted study section notes that the varying progress made by patients of different methadone service counsellors could not
be accounted for by the counsellors’ qualifications. Important instead were being administratively well organised and diligent, and
building on this by being actively problem-solving and therapeutic.
 Are we making progress on systems for treating ‘dual diagnosis’? According to commissioning guidance from UK medical and other
experts (see What would a good quality drug service look like?), one sign of a good quality substance use service is that it can “manage
the full range of complexity of need, including ... mental and associated physical health needs”. But back in 2002 official UK guidance
stressed that when the mental problems are severe, care “should be delivered within mental health services”, which “have a
responsibility to address the needs of people with a dual diagnosis”. In 2011 NICE echoed that advice. Yet we know that when assessed
in 2007, mental health services had not been able to adequately gear up for problem substance users among their caseloads. At a micro
level, some of the reasons why became apparent in interviews with mental health nurses. Though experienced in working with substance
using clients, to them these patients often seemed to pose an “impossible challenge” for which they lacked both skills and support. In
this organisational context (see Where should I start? in Alcohol Matrix cell D2), training the individual workers may not lead to improved
practice and outcomes, the finding in a study in London which tested a substantial training and supervision investment in dual diagnosis
for mental health case managers. Are things better now – do substance users find welcoming and effective care in mental health
services? Should substance use services take a more prominent role in aiding mental health services, perhaps even expanding their remit
and skilling up to themselves deal with the severe psychiatric problems so common among their caseloads? Or would that be
counterproductive and possibly dangerous in cases of severe illness? The issue of how to deal with these crossover patients just does not
seem to go away.
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